Abstract: The antiviral activity of 5-fluoro-uracil, 5-fluoro-2'-deoxyuridine and similar thymilydate synthetase inhibitors towards herpes viruses can be potentiated dramatically by combining these compounds with compounds having viral thymidine kinase inhibiting activity.

Abstract: Compositions and methods of manufacture for producing a medicament composition capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus. The present invention relates to such compositions and methods which are useful in administering drugs in a dose-to-effect manner such that sufficient drug is administered to produce precisely a desired effect. The invention also relates to a manufacturing technique that enables a therapeutic agent or drug to be incorporated into a flavored confectionary base and to compress or otherwise attach the solid confectionary mixture onto an appliance or holder.Employing the present invention the drug may be introduced into the patient's bloodstream almost as fast as through injection, and much faster than using the oral administration route, while avoiding the negative aspects of both of these methods. The present invention achieves these advantages by incorporating the drug into a compressed powder "candy" matrix.

Abstract: The small animal prophylactic dentifrice is a foam figure 10 jacketed by a minimally fine threaded netting 14 which, in concert with a flavor attractant, both encourages and results in positive dental care results for small animals.

Abstract: This invention relates to devices useful for the controlled delivery of one or more beneficial agents to an environment of use. More specifically, this invention concerns such devices which are powered by lyotropic liquid crystals. This invention also relates to the controlled delivery of one or more beneficial agents to an aqueous environment of use through the use of such lyotropic liquid crystal powered dispensing devices. Also disclosed are methods for the controlled delivery of one or more beneficial agents to an aqueous environment of use which comprise administering to or otherwise placing the devices of this invention in the environment of use.

Abstract: A hair conditioning shampoo is described, which contains C.sub.6, C.sub.8 and/or C.sub.10 alkyl sulfate and/or C.sub.6, C.sub.8 and/or C.sub.10 alkyl lower alkoxylate sulfate as an anionic detergent component, a water insoluble conditioning agent(s) from the group of silicones (preferably a certain type of aminosilicone), polyethylenes, paraffins, isoparaffins, microcrystalline waxes, C.sub.18-36(mixed) fatty acids or such triglycerides, high fatty alcohol ester of a high fatty acid (such as stearyl stearate), beeswax, cationic conditioning agent, such as a quaternary ammonium or any mixture thereof, and a stabilizer for the shampoo, in water. Among adjuvants that may be present are lauric monoethanolamide, cocodiethanolamide, and hydroxyethyl cellulose, other thickeners and viscosity modifiers, pH adjusting agents, antioxidants perfumes and colorants. The presence of the C.sub.6, C.sub.8 and/or C.sub.10 alkyl sulfate and/or C.sub.6, C.sub.8 and/or C.sub.

Abstract: The first part explains the discovery, and means to employ the discovery that whole, intact vesicles and liposomes are not the sole means of burden (drug) delivery by targeting molecules. The second part teaches the discovery of reverse loading of vesicles and liposomes to obtain fully functional core volume load of a useful burden without the trauma degradation of the active burden material, and with greatly extended shelf life.

Abstract: The application discloses a good-tasting and palatable gritty drug formulation, wherein the grittiness is associated as a part of a pleasurable organoleptic sensation, which contains a gritty and optionally bad-tasting or odoriferous drug and a seedy fibrous fruit, and optionally an aqueous medium and a gelling agent, and preferably also a sweetener and a flavoring agent, wherein the gritty drug is representatively an antihypercholesterolemic drug, especially a bile acid sequestrant, and particularly cholestyramine, a method for the preparation thereof, and a method of converting a gritty drug into a more readily-acceptable formulation which assists with patient compliance.

Abstract: The present invention concerns synthetic mica powder containing from 75 to 99% of the stoichiometrical composition of fluorine and/or having a shape in which the end face of a particle is laminated, a process for producing such synthetic mica powder, as well as cosmetics having synthetic mica powder blended therewith, in which the synthetic mica powder shows no leaching of fluorine ions and/or improved hold of oils due to lamination at the surface of the powder. Accordingly, in this invention, cosmetics excellent in extensibility, gloss, adherence and moldability, having an appearance of high chroma and of high stability and safety can be obtained.

Abstract: The present invention concerns synthetic mica powder containing from 75 to 99% of the stoichiometrical composition of fluorine and/or having a shape in which the end face of particle is laminated, process for producing such synthetic mica powder, as well as cosmetics having synthetic mica powder blended therewith, in which the synthetic mica powder shows no leaching of fluorine ions and/or improved hold of oils due to lamination at the surface of powder. Accordingly, in this invention, cosmetics excellent in extensibility, gloss, adherence and modability, having appearance of high chroma and of high stability and safety can be obtained.

Abstract: The process for the preparation of containers comprising two or more partial regions separated from each other of solid cast powder formulations having different colors employs containers into which separating bridges of a pasty composition have been injected, said composition being similar to the subsequently cast solid powder formulations. The bridges prevent the partial regions having different colors from coalescing.

Abstract: An injectable drug composition including a therapeutically effective amount of a lipophilic drug and a bile salt.

Abstract: A rapid-releasing oral particle pharmaceutical preparation with its unpleasant taste masked comprising a core and a film layer coating the core, the core at least containing a drug having an unpleasant taste and a water-swelling agent, and the film layer at least containing ethylcellulose and a water-soluble substance, the amount of the drug in the core being at most 40% (based on the final particle preparation and so on), the amount of the water-swelling agent being about 35% to about 70%, the amount of ethylcellulose in the film layer being about 3 to about 11%, and the amount of the water-soluble substance being about 0.1 to about 0.8 times the weight of the ethylcellulose.

Abstract: A substantially non-aqueous iodine microbicide composition comprising (a) a povidone-iodine in an amount of from 0.0005% to 1.0% by weight based on the total amount of the composition, and (b) a solvent comprising a lower alcohol having from 1 to 3 carbon atoms or a mixture of a lower alcohol having from 1 to 3 carbon atoms and a non-hydrated polyhydric alcohol, and an aerosol-type iodine microbicide composition containing the iodine microbicide composition.

Abstract: A liposome gel composition and method of preparing the same. The composition is composed of charged liposomes, at a relatively low lipid concentration, in a low-conductivity medium. The composition preferably contains a zwitterionic compound at its isoelectric point. The liposomes can be designed for cosmetic use, transdermal drug delivery, or enhanced retention on mucosal tissues, such as for ophthalmic use.

Abstract: Disclosed are aqueous aerosol droplets containing liposome or interacted liposome-drug or medication combination particles in a continuous phase of air or oxygen-enriched air advantageous for the treatment of a wide variety of diseases. The drug or medication is interacted with the liposome membrane so that on its rupture the drug or medication is not lost from the liposome. Different methods of preparation of the aerosol particles containing the liposome and interacted liposome-drug combination particles are described which can be used in small particle aerosol treatment. The majority of the aerosol droplets containing the liposome particles alone or with drugs has a diameter less than 5 microns and has an aerodynamic mass median diameter ranging from about 1 to 3 microns, and the liposome and interacted-liposome drug particles are substantially uniform in size and less than 1 micron in diameter.

Abstract: Pharmaceutical formulations are disclosed, adapted for preparing solid oral dosage forms (tablets, capsules, lozenges, etc.) having a regular and sustained release after administration. Said formulations comprise one or more active substances and a retarding base or matrix consisting of a polysaccharide of natural origin, alone or mixed with one or more natural or synthetic polymers which may be used to modify the release pattern so as to obtain a therapeutically effective formulation.

Abstract: This invention relates to a method of inhibiting fungal growth by employing an antifungal amount of a compound of formula (I): ##STR1##